Filter by Knowledge Space:
Aptar Pharma
PF
Aptar Pharma
Jose Ferrao and Pauline Faucard
Leachables Assessment from a New Generation of pMDI Using Low Global Warming Potential PropellantsGD
Aptar Pharma
Gerallt Williams and Gregoire Deraime
Filling and Dose Performance of pMDIs with New Low Global Warming Potential PropellantsJK
Aston Particle Technologies
David Wyatt and Jasdip Koner
Use of Isothermal Dry Particle Coating (iDPC) for the Development of High Dose Dry Powder InhalersAstraZeneca
KV
AstraZeneca
AstraZeneca
KY
Battelle
Catalent
MB
DFE Pharma
MM
Harro Höfliger
Honeywell
Hovione
Kindeva Drug Delivery
DROB
Kindeva Drug Delivery
David Riley and Olivia Brittain
An Evaluation of Solution and Suspension pMDIs Containing HFA152a and HFO1234ze Using Clinically Relevant Test MethodsLonza
Lund University
M2M Pharmaceuticals
Micro-Sphere SA
Monash University
Nanoform
Nanopharm
AZ
Nanopharm
Nanopharm
Irene Rossi and Paul Shields
Formulation Technologies Assessment for the Development of Intranasal Powders Comprising a PeptideOz-UK Limited
Oz-UK Limited
KS
PARI Pharma
Andrea Winzen and Karin Steinfuehrer
Development of a Pediatric Upper Airway Model as Add-on for a High Repeatability Test Stand for the Measurement of Valved Holding ChambersProveris Scientific Corporation
Recipharm
Sabrina Falloon and Adam Gibbons
Usability Evaluation of a Novel, User-Independent Unit Dose Nasal Spray via Human Factors StudiesRecipharm
Recipharm
Solvias
South East Technological University
AW
Team Consulting
Prem-Sagar Tank and Alastair Willoughby
Evolving Strategies for Designing a Sustainable InhalerTrudell Medical International
Trudell Medical International
Universidad de Valparaíso
Universidad de Valparaíso
University of Alberta
University of Alberta
University of Alberta
University of Applied Sciences Biberach
University of Applied Sciences Biberach
University of Coimbra
University of Coimbra
University of Hertfordshire
University of Otago
Rakesh Bastola and Shyamal Das
Influence of Lung Mucus on In Vitro Dissolution and Absorption of an Inhalable DrugUniversity of Parma
University of Parma
Upperton Pharma Solutions
Vectura
For further information, contact Richard Dalby.